Anti-CD30-MCC-DM1 showed linear and nonlinear PK characteristics in the single-dose PK of rats and cynomolgus monkeys, respectively, which were consistent with that of T-DM1 in the same dosage of rats and cynomolgus monkeys.32 Therefore, anti-CD30-MCC-DM1 was expected to exhibit promising druggability in the clinical setting. This evidence concerns the gene TNFRSF8 and Merkel cell skin cancer.